ADCT
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- ADC Therapeutics completed enrollment in the Phase 1b LOTIS-7 combination trial of ZYNLONTAJul 1, 2026
- ADC Therapeutics announced a strategic reorganization to support ZYNLONTA growth and regulatory objectivesJun 24, 2026
- ADC Therapeutics reported results from the Phase 3 LOTIS-5 confirmatory trial of ZYNLONTA plus rituximabJun 4, 2026
- ADC Therapeutics announced updated data from LOTIS-7 Phase 1b trial of ZYNLONTA® with bispecific antibody in relapsed/refractory diffuse large B-cell lymphomaDec 3, 2025
- ADC Therapeutics presents updated ZYNLONTA trial data in marginal zone lymphoma at ICML 2025Jun 16, 2025